Wilmore, Sarah
Rogers-Broadway, Karly-Rai
Taylor, Joe
Lemm, Elizabeth
Fell, Rachel
Stevenson, Freda K.
Forconi, Francesco
Steele, Andrew J.
Coldwell, Mark
Packham, Graham http://orcid.org/0000-0002-9232-5691
Yeomans, Alison
Funding for this research was provided by:
Cancer Research UK (C2750/A23669)
Bloodwise (14040, 14045, 16004, 13036, 18009)
Kay Kendall Leukaemia Fund (KKL0168)
Southampton Experimental Cancer Medicine and Cancer Research centres (C24563/A15581, C34999/A18087)
Article History
Received: 18 December 2020
Revised: 9 July 2021
Accepted: 2 August 2021
First Online: 16 August 2021
Declarations
:
: AJS received research funding from Janssen and Portola Pharmaceuticals and received consultancy payments from Portola Pharmaceuticals and Gilead. AJS holds stock in Portola Pharmaceuticals. All other authors have no relevant disclosures.
: The study was approved by the Institutional Review Boards at the University of Southampton (REC: H228/02/t).
: All patients provided written informed consent.
: Not applicable.